Investor Relations

VBL Therapeutics to Present at Upcoming June Conferences

June 14, 2017
Update on Long term Survival of VB-111 Treated Patients to be Presented at BIO on June 20

TEL AVIV, Israel, June 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced Prof. Dror Harats, CEO,  will provide a corporate overview at the 2017 BIO International Convention in San Diego and participate in a panel on novel approaches in immuno-oncology at  the JMP Securities Life Sciences Conference in New York City.

2017 BIO International Convention Presentation Details
Date: Tuesday, June 20, 2017
Time: 11:45 a.m. PDT
Presentation Room: Company Presentation Theater 3
Location: San Diego Convention Center, San Diego
Webcast: http://www.veracast.com/webcasts/bio/internationalconvention2017/17205139583.cfm

During the BIO presentation, Prof. Harats will discuss new data on long term survival with the company’s lead candidate VB-111, across different oncology indications. Previously, VBL reported the effect on median overall survival from an all-comers Phase 1 trial, as well from Phase 2 trials in recurrent glioblastoma (rGBM), ovarian and thyroid cancers.  The company continues to follow treated patients, and at BIO, will provide an overview of patients that were, or still are, long-term survivors following VB-111 therapy.

JMP Securities Life Sciences Conference Panel Discussion Details
Topic: Immuno-Oncology: Novel Approaches
Date: Wednesday, June 21, 2017
Time: 11:00 a.m. EDT
Presentation Room: Track 2 - Fontainebleau
Location: St. Regis New York

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the clinical development of ofranergene obadenovec (VB-111) and its therapeutic potential, ongoing and planned clinical trials and clinical results, including the timing thereof, our other pipeline candidates, including the clinical development and therapeutic potential of our VB-600 series of pipeline candidates and Lecinoxoids in NASH, our new Modiin facility and our cash position and financial outlook. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. In particular, results from our pivotal Phase 3 clinical trial of ofranergene obadenovec (VB-111) in rGBM may not support approval of ofranergene obadenovec for marketing in the United States, notwithstanding the positive results seen in prior clinical experience. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:
Michael RiceLifeSci Advisors, LLCmrice@lifesciadvisors.com
(646) 597-6979

MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
(646) 627-8384

Primary Logo